Suppr超能文献

澳大利亚仿制药价格高昂——增加竞争或许会有所帮助。

High prices for generics in Australia - more competition might help.

作者信息

Bulfone Liliana

机构信息

Health Economics Unit, Faculty of Health, Medicine, Nursing and Behavioural Science, Deakin University, Melbourne, VIC 3125.

出版信息

Aust Health Rev. 2009 May;33(2):200-14. doi: 10.1071/ah090200.

Abstract

It is commonly believed that dispensed prices of medicines in Australia are substantially lower than those in other developed countries, particularly the US. This article reports the results of an analysis comparing dispensed prices for the most commonly prescribed and the highest cost items in Australia with dispensed prices in the US. Although a large majority of items are less expensive in Australia than in the US, Australian prices are higher for a substantial number of products, particularly generic drugs. This article examines various policies affecting the pricing of generics in Australia. It is postulated that the main cause for higher prices for a substantial number of generic products is the lack of price competition. This results from government policy which ensures that a price reduction by one company is communicated immediately to all competitors in that market along with an invitation to match the reduced price. The dominant strategy for all suppliers is to only reduce their price in response to a reduction in price by a competitor. The result is a lack of differentiation in pricing across brands of a medicine on the Schedule of Pharmaceutical Benefits. The government could improve the structure of the generics market and encourage greater competition by ceasing to disclose competitor firms' offers to other competitors. The government could conduct pricing reviews of each generic product relatively infrequently (eg, only once annually or every 18 months). At the time of the pricing review, the government would request confidential offers on price for a generic from all players in the market. Brands should then all be listed under the Pharmaceutical Benefits Scheme (PBS) at the offered price. Prices offered by the individual supplier would apply until the next pricing review. The PBS would continue to subsidise up to the price of the lowest priced brand, with brand premiums applying to all brands priced higher than the benchmark price. Such an approach would provide opportunity for players in the market to capture market share by being the lowest priced brand.

摘要

人们普遍认为,澳大利亚药品的配药价格远低于其他发达国家,尤其是美国。本文报告了一项分析结果,该分析将澳大利亚最常处方和成本最高的药品的配药价格与美国的配药价格进行了比较。尽管绝大多数药品在澳大利亚比在美国便宜,但仍有相当数量的产品在澳大利亚价格更高,尤其是仿制药。本文研究了影响澳大利亚仿制药定价的各种政策。据推测,相当数量仿制药价格较高的主要原因是缺乏价格竞争。这是政府政策导致的结果,该政策确保一家公司降价会立即告知该市场的所有竞争对手,并邀请它们匹配降价。所有供应商的主导策略是仅在竞争对手降价时才降低自己的价格。结果是药品福利计划清单上一种药品的不同品牌在定价上缺乏差异。政府可以通过停止向其他竞争对手披露竞争公司的报价来改善仿制药市场结构并鼓励更大的竞争。政府可以相对不频繁地(例如,仅每年一次或每18个月一次)对每种仿制药进行定价审查。在定价审查时,政府将要求市场上所有参与者提供仿制药的保密价格报价。然后所有品牌都应以所报价格列入药品福利计划(PBS)。个别供应商提供的价格将适用至下次定价审查。PBS将继续补贴至最低价格品牌的价格,品牌溢价适用于所有价格高于基准价格的品牌。这种方法将为市场参与者提供机会,通过成为最低价格品牌来获取市场份额。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验